Abstract
Introduction Coronavirus disease 2019 (COVID-19) and influenza share similar symptoms, which hampers diagnosis. Given that they require different containment and treatment strategies, fast and accurate distinction between the two infections is needed. This study evaluates the sensitivity and specificity of the LumiraDx SARS-CoV-2 & Flu A/B Test for simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza A/B from a single nasal swab.
Methods Nasal samples were collected from patients as part of the ASPIRE (NCT04557046) and INSPIRE (NCT04288921) studies at point-of-care testing sites in the USA. ASPIRE study participants were included after developing COVID-19 symptoms in the last 14 days or following a positive SARS-CoV-2 test in the last 48 hours. INSPIRE study participants were included after developing influenza symptoms in the last 4 days. Samples were extracted into proprietary buffer and analysed using the LumiraDx SARS-CoV-2 & Flu A/B Test. A reference sample was taken from each subject, placed into universal transport medium and tested using reference SARS-CoV-2 and influenza reverse transcription polymerase chain reaction (RT-PCR) tests. The test and reference samples were compared using the positive percent agreement (PPA) and negative percent agreement (NPA), together with their 95% confidence intervals (CI).
Results Analysis of the data from the ASPIRE (N=124) and INSPIRE (N=159) studies revealed high levels of agreement between the LumiraDx SARS-CoV-2 & Flu A/B Test and the reference tests in detecting SARS-CoV-2 (PPA=95.5% [95% CI: 84.9%, 98.7%]; NPA=96.0% [95% CI: 90.9%, 98.3%]), influenza A (PPA=83.3% [95% CI: 66.4%, 92.7%]; NPA=97.7% [95% CI: 93.4%, 99.2%]) and influenza B (PPA=80.0% [95% CI: 62.7%, 90.5%]; NPA=95.3% [95% CI: 90.2%, 97.9%]).
Conclusions The LumiraDx SARS-CoV-2 & Flu A/B Test shows a high agreement with the reference RT-PCR tests while simultaneously detecting and differentiating between SARS-CoV-2 and influenza A/B.
Trial registration, ClinicalTrials.gov identifier: NCT04557046 and NCT04288921
Competing Interest Statement
Jayne Ellis is a consultant to LumiraDx. Poppy Guest, Vicki Lawson, Julia Loecherbach, Nigel 279 Lindner and Andrew McCulloch are employees of LumiraDx.
Clinical Trial
NCT04557046 and NCT04288921
Funding Statement
This study was funded by LumiraDx.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the WIRB-Copernicus Group gave ethical approval for the ASPIRE study under protocol number CS-1211-01 (WCG IRB 20201775). IRB of the WIRB-Copernicus Group gave ethical approval for the INSPIRE study under protocol numbers CS-LUMFLURSV19-01 (CS-1176-01; WCG IRB 20193352) and CS-LUMFLURSV19-01A (CS-1176-01A; WCG IRB 20193211).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
Data availability
All data generated or analysed during this study are included in this published article as supplementary information files.